Distinguish NMOSD from MS and MOGAD before choosing therapy
Heidelberg emphasizes that NMOSD was historically considered an MS variant but is now recognized as a distinct antibody-mediated disease. Freiburg's neuroimmunology clinic treats NMOSD and MOGAD as separate conditions. This distinction matters because diagnostic criteria, relapse risk and long-term immunotherapy differ.
- Clinical pattern of optic neuritis, myelitis or brainstem symptoms
- Serum AQP4-IgG testing with an appropriate assay
- MOG-IgG testing when the phenotype and AQP4 result make MOGAD a relevant differential
- Brain and spinal-cord MRI
- CSF examination when clinically indicated
- Review for MS and other inflammatory, infectious, vascular or systemic autoimmune mimics
AQP4-IgG is central to the diagnostic pathway
Heidelberg describes AQP4-IgG as a major diagnostic and pathophysiological marker for NMOSD and reports that a large proportion of patients are seropositive. A positive result must still be interpreted with the clinical syndrome and imaging rather than used as a stand-alone screening label.
MRI should cover the structures involved in the attack
NMOSD commonly affects the optic nerves and spinal cord. Heidelberg's patient pathway uses MRI of the spinal cord and brain as part of diagnosis and follow-up. For an international second opinion, send original DICOM imaging rather than only a written radiology summary whenever the hospital requests it.
An acute NMOSD attack is time-sensitive care
Heidelberg describes acute attacks as being treated with high-dose intravenous corticosteroids over several days or, alternatively or when needed, an apheresis-based blood-wash treatment. Because attacks can cause major visual or spinal-cord disability, sudden visual loss, rapidly progressing weakness or breathing impairment requires urgent local neurological care rather than waiting for planned travel.
Relapse prevention is a separate long-term treatment decision
Heidelberg notes that preventive immunotherapy is started early to reduce further attacks, using therapies that target antibody-producing immune pathways or other immunosuppressive strategies. The choice depends on AQP4 status, previous attacks, disability, infection risk, comorbidities, pregnancy plans and prior treatment. The exact drug should be selected by a neuroimmunology specialist rather than from a generic online list.
Monitoring continues after treatment selection
Heidelberg describes regular blood testing and neurological assessment during long-term therapy, with repeat MRI at larger intervals. International patients should clarify which monitoring must be performed by the German center and which can be coordinated with a neurologist at home.
Second opinion is particularly valuable when the diagnosis is uncertain
Freiburg explicitly offers first diagnosis, differential diagnosis, second opinion and therapy escalation for NMOSD, MOGAD and other inflammatory CNS diseases. A second opinion can be useful when AQP4 testing is negative, the MRI pattern is atypical, the patient was originally diagnosed with MS or relapses continue despite preventive therapy.
What to send for a German NMOSD second opinion
The record package should document both the diagnostic evidence and the timing and severity of previous attacks.
- Neurology and neuroimmunology reports
- AQP4-IgG result including assay/laboratory information when available
- MOG-IgG result if performed
- Brain, orbital and spinal-cord MRI in original DICOM format when requested
- CSF results
- Visual testing and ophthalmology/neuro-ophthalmology reports for optic neuritis
- Details of each previous relapse and recovery
- Previous high-dose steroid or apheresis treatment
- Current and previous long-term immunotherapy
- A specific question: confirm diagnosis, distinguish NMOSD from MOGAD/MS, review relapse treatment or optimize prevention
Official sources
Sources last checked 2026-09-01. Clinical pathways, eligibility and hospital procedures can change; confirm current requirements directly with the treating center.
- NMOSD disease, diagnosis and treatment pathway — Heidelberg University Hospital ↗
- NMOSD – AQP4 and MOG antibody diagnostics — Heidelberg University Hospital ↗
- Inflammatory CNS diseases outpatient clinic — University Medical Center Freiburg ↗
- Neuroimmunology / NMO outpatient care — Charité – Universitätsmedizin Berlin ↗